Developing an artificial heart valve project addresses several critical clinical needs in cardiovascular care. Valvular heart diseases that may be provoked by acute rheumatic fever, congenital anomalies, or degenerative changes occur very frequently in today's population and might become the cause of heart failure and sudden cardiac death among affected patients. Existing therapies like mechanical or biological valves have several drawbacks, including the requirement of long-term anticoagulation, less product durability, and the risk of valve failure. As a result, there is a clinical mandate for the development of more effective artificial heart valves that can achieve better biocompatibility, mechanical performance, and durability. The development of these new valves should ensure a low thromboembolic risk, lower dependency on anticoagulant therapies, and better hemodynamic profiles. Furthermore, the integration of diagnostic capabilities within the valve design can enable continuous monitoring of valve function and patient condition, leading to more personalized and effective management strategies. By focusing on these clinical needs, the artificial heart valve project can significantly enhance patient outcomes, reduce healthcare costs, and improve the overall quality of life for individuals with heart valve diseases.